Synthesis and preclinical evaluation of novel $^{18}$F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with $^{18}$F-DCFPyl and $^{18}$F-PSMA-1007

Stephanie Robu1*, Alexander Schmidt1, Matthias Eiber2, Margret Schottelius1, Thomas Günther1, Behrooz Hooshyar Yousefi2, Markus Schwaiger2 and Hans-Jürgen Wester1

Abstract

Background: Due to its high and consistent expression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) represents an ideal target for molecular imaging and targeted therapy using highly specific radiolabeled PSMA ligands. To address the continuously growing clinical demand for $^{18}$F-labeled PSMA-probes, we developed two novel Glu-urea-Glu-(EuE)-based inhibitors, EuE-k-$^{18}$F-FBOA (1) and EuE-k-β-a-$^{18}$F-FPyl (2), both with optimized linker structure and different $^{18}$F-labeled aromatic moieties. The inhibitors were evaluated in a comparative preclinical study with $^{18}$F-DCFPyl and $^{18}$F-PSMA-1007.

Results: Radiolabeling procedures allowed preparation of (1) and (2) with high radiochemical yields (67 ± 7 and 53 ± 7%, d.c.) and purity (> 98%). When compared with $^{18}$F-DCFPyl ($IC_{50} = 12.3 ± 1.2$ nM) and $^{18}$F-PSMA-1007 ($IC_{50} = 4.2 ± 0.5$ nM), both metabolically stable EuE-based ligands showed commensurable or higher PSMA affinity ($IC_{50} = 4.2 ± 0.4$ nM (1), $IC_{50} = 1.1 ± 0.2$ nM (2)). Moreover, 1.4- and 2.7-fold higher internalization rates were observed for (1) and (2), respectively, resulting in markedly enhanced tumor accumulation in LNCaP-tumor-bearing mice ((1) $12.7 ± 2.0$% IA/g, (2) $13.0° ± 1.0$% IA/g vs. $7.3 ± 1.0$% IA/g ($^{18}$F-DCFPyl), $7.1 ± 1.5$% IA/g ($^{18}$F-PSMA-1007), 1 h p.i.). In contrast to (1), (2) showed higher kidney accumulation and delayed clearance kinetics. Due to the high hydrophilicity of both compounds, almost no unspecific uptake in non-target tissue was observed. In contrast, due to the less hydrophilic character ($logP = −1.6$) and high plasma protein binding (98%), $^{18}$F-PSMA-1007 showed uptake in non-target tissue and predominantly hepatobiliary excretion, whereas, $^{18}$F-DCFPyl exhibited pharmacokinetics quite similar to those obtained with (1) and (2).

Conclusion: Both $^{18}$F-labeled EuE-based PSMA ligands showed excellent in vitro and in vivo PSMA-targeting characteristics. The substantially higher tumor accumulation in mice compared to recently introduced $^{18}$F-PSMA-1007 and $^{18}$F-DCFPyl suggests their high value for preclinical studies investigating the effects on PSMA-expression. In contrast to (2), (1) seems to be more promising for further investigation, due to the more reliable $^{18}$F-labeling procedure, the faster clearance kinetics with comparable high tumor uptake, resulting therefore in better high-contrast microPET imaging as early as 1 h p.i.

Keywords: PSMA, $^{18}$F-labeled EuE-based inhibitors, $^{18}$F-DCFPyl, $^{18}$F-PSMA-1007, PET prostate Cancer imaging
Background
During the last several years, the prostate-specific membrane antigen (PSMA) and corresponding radiolabeled inhibitors have become one of the most extensively investigated target/tracer pair for molecular imaging and radioligand therapy of prostate cancer (PCa). Due to readily availability of $^{68}$Ge/$^{68}$Ga-generators, strong emphasis has been placed on the development and optimization of $^{68}$Ga-labeled PET probes for clinical imaging of PCa. However, the use of $^{68}$Ga for labeling of PSMA inhibitors has severe limitations. Based on the small generator sizes, the overall activity that can be produced in a single batch production is quite low and only sufficient in optimal conditions for three to four patients (maximum of 1500 MBq). In addition, due to short half-life of only 68 min, $^{68}$Ga-PSMA ligands have to be produced in big centers several times a day to cope with high clinical need. Due to the unique radionuclide characteristics of $^{18}$F ($\tau_{1/2}=109.7$ min, $E_{\gamma}=0.63$ MeV) and its corresponding advantages for PET imaging combined with large-scale production by means of even small cyclotrons, several groups have focused on the development of $^{18}$F-labeled PSMA inhibitors for PCa imaging [1–6]. One of the first $^{18}$F-labeled PSMA ligand was $^{18}$F-DCFBC, demonstrating the ability for detection of high-grade primary PCa and metastatic lesions [4]. However, $^{18}$F-DCFBC possessed some features that could be improved through further refinements in the chemical structure. Especially, the high plasma protein binding of the tracer, which results in slow clearance kinetics and high blood pool activity can interfere with the detection of lower avidity or smaller tumor lesions [7, 8].

The second-generation inhibitor $^{18}$F-DCFPyl, developed by the same group [2], showed five times higher PSMA affinity, improved tumor uptake, and rapid plasma clearance, resulting in higher tumor-to-blood and tumor-to-background ratios and lower accumulation in the liver compared to $^{18}$F-DCFBC. However, a considerable kidney and salivary gland uptake was observed [9].

Recently, $^{18}$F-PSMA-1007, a novel $^{18}$F-labeled tracer based on the DKFZ-617-scaffold [1, 10], was reported. First human studies exhibit excellent sensitivity of $^{18}$F-PSMA-1007 for the detection of small lymph node metastases. In contrast to the renal clearance of $^{18}$F-PSMA-1007 in animal studies, predominant hepatobiliary excretion with reduced urinary uptake was observed in this first series of patients. Overall, a major disadvantage is the slow tracer kinetic of $^{18}$F-PSMA-1007, resulting in favorable tumor-to-background ratios and an increased tumor uptake up to 50% at late imaging time points (3 h p.i.) [11].

In this study, we aimed towards the development of novel $^{18}$F-labeled PSMA inhibitors, exploiting optimized $^{18}$F-labeling strategies and the increasing experience concerning the structural requirements for optimal ligand binding to further improve the in vitro and in vivo PSMA-targeting characteristics in comparison to the currently available $^{18}$F-labeled compounds. Up to date, the development of PSMA inhibitors has been mainly based on the Lys-urea-Glu (KuE) core as binding motif [1, 2, 12]. However, in a preliminary study, the design of PSMA inhibitors containing a EuE (Glu-urea-Glu) binding motif was described [13]. A direct comparison of both urea-based binding motifs was demonstrated by Hillier et al., who evaluated different $^{99m}$Tc-labeled PSMA inhibitors, based on either a KuE- or a EuE-binding motif with related linker structures and chelator moieties [14]. In vitro and in vivo data successfully demonstrated, the beneficial influence of a free carboxylic group in the linker region, i.e., by introduction of an amino acid to the EuE-based binding motif. This structural difference had pronounced effect on the hydrophilicity of the ligand and resulted in enhanced PSMA affinity, higher internalization efficiency, higher tumor accumulation, and favorable clearance kinetics [14]. Therefore, we designed two alternative EuE-based ligands suitable to be labeled with either chemo-selective oxime ligation (as a generally applicable $^{18}$F-labeling strategy for peptidic ligands) or established acylation chemistry with $^{18}$F-FPyl-TFP. Both $^{18}$F-labeled analogs, named EuE-k-$^{18}$F-FBOA and EuE-k-ß-a-$^{18}$F-FPyl, were subsequently evaluated in terms of PSMA affinity, internalization in LNCaP PCa cells, metabolic stability, micro PET imaging, and in vivo biodistribution. The recently introduced ligands, $^{18}$F-DCFPyl [2, 9] and $^{18}$F-PSMA-1007 [1, 15], were included in this evaluation process to allow a direct comparison of all four tracers (Fig. 1).

Methods
Chemical synthesis and radiolabeling
A detailed description of the chemical synthesis and radiolabeling of all compounds is provided in the supporting information.

Lipophilicity and plasma protein binding
To a solution of $^{18}$F-labeled peptide (0.5–1.0 MBq) in 0.5 mL PBS (pH 7.4), 0.5 mL of octanol was added ($n=6$). The vials were vortexed vigorously for 3 min. To achieve efficient phase separation, vials were centrifuged for 5 min at 6000g in a Biofuge 15 (Heraeus Sepatech, Osterode, Germany). Aliquots (100 μL) of the aqueous and the octanol phase were collected and the radioactivity concentrations in the respective samples were quantified using a γ-counter. The Log $P_{O/PBS}$ values were calculated from the means of $n=6$ separate determinations.
Plasma protein binding of the tracers was determined using an analytical Chiralpak human serum albumin (HSA) column (50 × 3 mm, 5 μm) according to a previously published protocol with minor changes [16].

**In vitro evaluation**

**Cell culture**

PSMA overexpressing LNCaP cells (CLS: 300265) were cultured in DMEM/Nutrition Mix F-12 with Glutamax-I (1:1) (Invitrogen, Life Technologies, Darmstadt, Germany) supplemented with 10% FCS and were maintained at 37 °C in a 5% CO₂/humidified air atmosphere. For IC₅₀ determination, approximately 150,000 cells/well were seeded on 24-well plates 1 day prior to the experiment. For internalization studies, 125,000 cells/well were seeded in PLL-coated 24-well plates. For cell counting, a Countesse automated cell counter (Invitrogen, Carlsbad, USA) was used.

**Determination of IC₅₀ and internalization studies**

PSMA affinity and internalization kinetics of the ¹⁸F-labeled compounds were determined according to a previously published protocol [17]. A detailed description is provided online in the supporting information.

Competitive binding experiments (IC₅₀) were carried out using PSMA-expressing LNCaP cells and ([¹²⁵I]-BA)KuE as standard radioligand. Internalization kinetics of the ¹⁸F-labeled derivatives were also performed using PSMA-expressing LNCaP cells and ([¹²⁵I]-BA)KuE (0.2 nM) as an internal reference. Data were corrected for non-specific internalization in the presence of 100 μM 2-phosphonomethyl pentanedioic acid (PMPA) and normalized to the specific internalization observed for the radioiodinated reference compound assayed in a parallel experiment. Data represent means ± SD (n = 3).

**Metabolite analyses**

Approximately 60–70 MBq of the ¹⁸F-labeled inhibitors were injected into the tail vein of severe combined immunodeficiency (SCID) mice. The animals were sacrificed 1 h p.i., blood and urine were collected, and kidneys were dissected and after freezing with liquid nitrogen, homogenized with a ball mill and extracted with 1 mL PBS containing 200 nmol PMPA. After centrifugation (15,000g) and ultrafiltration, the extracts were analyzed by reversed phase high-performance liquid chromatography (RP-HPLC). Blood samples were centrifuged to separate the plasma from the blood cells. Additionally, plasma proteins were removed by precipitation with acetonitrile (10 min, on ice), subsequent centrifugation and ultrafiltration. The blood extracts and the urine samples were analyzed using RP-HPLC. For RP-HPLC, a Nucleosil 100 C18 (5 μm, 125 × 4.0) column and different reaction conditions.
HPLC-systems were used (EuE-based inhibitors: flow rate: 2 mL/min; Gradient: 0–30% B in 20 min; HPLC-System A (see Additional file 1); 18F-PSMA-1007: flow rate: 1.5 mL/min; Gradient: 5–55% B in 10 min; HPLC-System B (see Additional file 1); solvent A: 0.1% trifluoroacetic acid (TFA) in water, solvent B: 0.1% TFA in MeCN).

In vivo evaluation

General

All animal experiments were conducted in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval no. 55.2-1-54-2532-71-13).

The LNCaP cells were attached from the surface of the culture flask using Trypsin/EDTA (0.05 and 0.02%) in PBS, centrifuged, and resuspended in culture medium. After cell counting, the cells were again centrifuged and resuspended 1:1 in serum-free culture medium and Matrigel (BD Biosciences, Germany). Concentrations of the cell suspension were approximately 1 x 10^7 cells/200 μL.

Animal model

To induce LNCaP tumor growth, male CB-17 SCID mice (6–8 weeks, Charles River Laboratories, Sulzfeld, Germany) were inoculated subcutaneously onto the right shoulder with LNCaP cells (approximately 1 x 10^7 cells/200 μL. DMEM/Nutrition Mix F-12 with Glutamax-I (1:1) medium and Matrigel (BD Biosciences, Germany) (1:1)). After 3–5 weeks, tumor size reached 4–8 mm in diameter, and the animals were used for in vivo studies.

Small-animal PET imaging

In vivo imaging studies were performed using a Siemens Inveon small-animal PET scanner. Mice were injected into the tail vein with approx. 0.9–1 MBq of the respective 18F-labeled compound under isoflurane anesthesia. For competition experiments, 2-PMPA (1 μmol = 226 μg/mouse) was coinjected. Dynamic images were recorded for 1.5 h after on-bed injection. Reconstruction of the images was carried out using three-dimensional ordered-subsets expectation maximum algorithm with out scanner and attenuation correction. Data analysis was carried out using Inveon Workplace software.

Biodistribution

About 0.8–1 MBq of the 18F-labeled tracer were injected into the tail vein of the mice (n = 8) under isoflurane anesthesia. Animals were sacrificed at 1 and 2 h p.i.; the organs of interest were dissected, and the activity in the weighed tissues samples was quantified using a γ-counter.

Results

Chemical synthesis

The rBu-protected PSMA binding motifs (OrBu) EuE(OrBu)_2 and (OrBu)KuE(OrBu)_2 were synthesized in 84 and 92% yield via three steps by solution phase synthesis as previously described [17]. The DCFPyl precursor (Fig. 1) was obtained by direct deprotection of (OrBu)KuE(OrBu)_2 using TFA (68% yield after preparative RP-HPLC). The EuE-based- and PSMA-1007-precursors (Fig. 1, Additional file 1: Figure S1A) were prepared via solid phase peptidic synthesis. The respective labeling precursors were cleaved from the resin using TFA, with concomitant removal of acid labile protecting groups (54–63% yield after RP-HPLC purification). The corresponding cold reference ligands EuE-k-β-a-FPyl, F-DCFPyl, and F-PSMA-1007 were subsequently prepared by direct conjugation of the respective precursors with 2,3,5,6-tetrafluorophenyl 6-fluoronicotinate under basic conditions and were obtained in 82, 75, and 87% yield after RP-HPLC purification, respectively. EuE-k-FBOA was obtained via chemo-selective oxime ligation of EuE-k-Aoa with 4-fluorobenzaldehyde under acidic aqueous conditions in 87% yield after RP-HPLC purification (Additional file 1: Figure S1A). The identity of all final products was confirmed by ESI-MS.

18F-radiolabeling

The radiosynthesis of the prosthetic groups 18F-FBA and 18F-FPyl-TFP was performed according to a previously published approach (Additional file 1: Figure S1B) [18, 19]. 18F-fluoride was directly eluted with an alcoholic solution (EtOH/MeOH) of the corresponding quaternary ammonium precursor salt, followed by heating of the resulting 18F-fluoride salt in a suitable solvent (MeCN/BuOH/EtOH, DMSO) without any additives or base. The 18F-labeled prosthetic groups 18F-FBA and 18F-FPyl-TFP were isolated via SPE extraction procedures [18, 19], which allowed quantitative separation from unreacted labeling precursor. 18F-FBA was synthesized within 35 min with high RCY (70–84%, d.c.) and high RCP (> 94%, n = 4). 18F-FPyl-TFP in 53–78% RCY (n = 12, d.c.) with > 75% RCP within 35 min. Coupling of 18F-FPyl-TFP was performed without further purification.

One-step oxime ligation of 18F-FBA and EuE-k-Aoa (3, 2 μmol) generally resulted in conjugation yields > 98% (n = 4) within 15 min at 60 °C. RP-HPLC isolation of EuE-k-18F-FBOA afforded the 18F-labeled product in high RCY (56–75%, d.c.) based on 18F-FBA and RCP (> 98%) in a synthesis time of app. 50 min (Fig. 1).

The acylation of the EuE-k-β-a and DCFPyl precursors (3.9 μmol, respectively) with 18F-FPyl-TFP was highly efficient, with conjugation yields of about 93% and 90%, respectively. In contrast, only very low conjugation yields of about 21% were achieved during the synthesis of 18F-
PSMA-1007 (Fig. 1). After RP-HPLC purification, RCYs of 45–64% (EuE-k-β-a-18F-FPyl), 45% (18F-DCFPyl), and 10% (18F-PSMA-1007) (d.c.) in a preparation time of about 40–50 min for all ligands were achieved, respectively. RCPs of the purified 18F-labeled peptides (n.c.a.) were > 98%.

**In vitro studies**

Binding affinities (IC\(_{50}\)) of the cold reference ligands EuE-k-FBOA, EuE-k-β-a-FPyl, F-DCFPyl, and F-PSMA-1007 were determined in a competitive binding assay using LNCaP human PCa cells and (\(^{125}\)I)-I-BA)KuEp as radioligand (0.2 nM) [20]. Inhibition curves of the respective PSMA inhibitors are shown in the Additional file 1: Figure S2 and data are summarized in Fig. 2a.

EuE-k-FBOA and F-PSMA-1007 exhibited nearly identical and high affinities towards PSMA, whereas F-DCFPyl showed a threefold lower binding affinity. The highest PSMA affinity was observed for EuE-k-β-a-FPyl with an IC\(_{50}\) 4– to 12-fold higher than that determined for EuE-k-FBOA, F-PSMA-1007, and F-DCFPyl, respectively.

In addition, marked differences in the internalization efficiency of the 18F-labeled EuE-based inhibitors in comparison to the two reference compounds 18F-DCFPyl and 18F-PSMA-1007 were observed (Fig. 2a). Compared to EuE-k-18F-FBOA, EuE-k-β-a-18F-FPyl showed substantially (twofold) enhanced internalization into LNCaP cells and exhibited the highest internalization efficiency of all compounds investigated in this study. Despite significant different PSMA affinities, 18F-DCFPyl and 18F-PSMA-1007 showed identical internalization rates, but markedly lower overall internalization into PSMA-expressing cells when compared to the 18F-labeled EuE-based compounds (Fig. 2a, Additional file 1: Figure S3).

**Lipophilicity and plasma protein binding**

The lipophilicities and human serum albumin (HSA) binding of all 18F-labeled compounds are summarized in Fig. 2b. Although the logP values of EuE-k-18F-FBOA and 18F-DCFPyl were nearly identical (−3.2 and −3.4, respectively) and the logP of EuE-k-β-a-18F-FPyl was even lower by an order of magnitude (−4.2), all three compounds exhibited similar, low plasma protein binding in the range of 12–14%. Due to its significantly higher lipophilicity (−1.6), a markedly enhanced plasma protein binding of 98% was found for 18F-PSMA-1007.

**Metabolite analysis**

The metabolic stability of the 18F-labeled EuE-based compounds EuE-k-18F-FBOA and EuE-k-β-a-18F-FPyl, as well as of 18F-PSMA-1007 was investigated in CD-1 mice (1 h p.i.). The metabolic stability of 18F-DCFPyl in mice has been reported elsewhere [21]. No in vivo degradation of both EuE-based tracers was observed in blood, urine, and kidneys (100% intact tracer) at 1 h p.i., while 18F-PSMA-1007 showed a slight in vivo degradation to a more hydrophilic metabolite, amounting to 2% of the total activity in the urine and 4% in the kidneys at 1 h p.i. (Additional file 1: Figure S4).

**Small-animal PET studies**

Dynamic micro PET imaging (0–90 min p.i.) of EuE-k-18F-FBOA, EuE-k-β-a-18F-FPyl, 18F-DCFPyl, and 18F-PSMA-1007 was carried out in LNCaP-tumor-bearing SCID mice (Fig. 3). A comparison of the pharmacokinetics of the four radiofluorinated inhibitors as measured by micro PET revealed a slightly enhanced tracer uptake of 18F-DCFPyl in the liver compared to the other 18F-labeled analogs. Increased tracer accumulation in the gallbladder was observed for 18F-PSMA-1007, probably due to a slight shift from renal to hepatobiliary excretion. In addition, 18F-PSMA-1007 displayed a delayed blood clearance (Additional file 1: Figure S5), due to its high-pronounced background activity in micro PET images.

In contrast, the EuE-based inhibitors and 18F-DCFPyl displayed rapid blood clearance (Additional file 1: Figure S5) with low unspecific whole body uptake and predominant renal clearance. Although all three inhibitors exhibited similar low plasma protein binding, EuE-k-β-a-18F-FPyl showed slightly increased background activity in micro PET. Interestingly, compared to the reference ligands 18F-PSMA-1007 and 18F-DCFPyl, both 18F-labeled EuE-based inhibitors, revealed enhanced uptake in the salivary and lacrimal glands.

Due to the enhanced internalization efficiency of the EuE-based inhibitors, markedly higher uptake in tumor lesions was observed compared to 18F-DCFPyl and 18F-PSMA-1007. Tracer uptake of EuE-k-18F-FBOA and EuE-k-β-a-18F-FPyl into tumor and kidneys is specific and PSMA-mediated, as demonstrated by blocking experiments with PMA (Fig. 3).

**Biodistribution**

A comparison of the in vivo biodistribution of the EuE-based inhibitors EuE-k-18F-FBOA and EuE-k-β-a-18F-FPyl and of the EuK analogs 18F-DCFPyl and 18F-PSMA-1007 in LNCaP-tumor-bearing SCID mice (1 h (n = 4) and 2 h p.i. (n = 4)) is shown in Fig. 4. EuE-k-18F-FBOA, EuE-k-β-a-18F-FPyl, and 18F-DCFPyl exhibited similar pharmacokinetics with fast renal excretion and low activity levels in non-target tissues. Interestingly, while all other compounds show low, but detectable liver accumulation, nearly no uptake for EuE-k-β-a-18F-FPyl was observed, which resulted in high tumor-to-liver ratios (Fig. 5) for this tracer. In contrast, 18F-PSMA-1007
showed markedly slower pharmacokinetics with increased and delayed delivery of the tracer in non-target tissue, the gastrointestinal tract and PSMA-mediated organs, like the spleen, kidneys, and adrenal glands over time (2 h p.i.). The high plasma protein binding and therefore delayed blood pool clearance of $^{18}$F-PSMA-1007 leads to low tumor-to-blood and tumor-to-spleen ratios, especially 2 h p.i. (Fig. 5; Additional file 1: Figure S5).

All compounds generally show high but variable tracer uptake in organs with physiological expression of the murine PSMA-variant, like the kidneys, the adrenal glands, and the spleen [22, 23]. However, of the compounds investigated, EuE-k-$^{18}$F-FBOA showed the lowest accumulation in these organs, resulting in high tumor-to-organ, and especially high tumor-to-kidney ratios (Fig. 5).

In comparison to the other two tracers, the EuE-based inhibitors EuE-k-$^{18}$F-FBOA and EuE-k-$\beta$-a-$^{18}$F-FPyl showed the highest tumor uptake at 1 and 2 h p.i.

**Discussion**

The present study was focused on the development of novel $^{18}$F-labeled EuE-based PSMA inhibitors with optimized PSMA-targeting characteristics and favorable pharmacokinetics. To ensure a valid assessment of the new tracers, two recently introduced tracers, $^{18}$F-PSMA-1007 and $^{18}$F-DCFPyl, were coevaluated.

For efficient radiolabeling of both structurally related EuE-based ligands, the preparation of the $^{18}$F-labeled synthons $^{18}$F-FBA and $^{18}$F-FPyl-TFP was carried out using a recently introduced approach allowing for the
direct conversion of an onium salt precursor into a $^{18}$F-labeled compound without the need of time-consuming azeotropic drying steps and addition of a base or other ingredients [18, 19].

Radiolabeling of both prosthetic groups was achieved with high RCYs comparable to those described in literature [18, 19]. However, in comparison to the oxime ligation with the $^{18}$F-labeled benzaldehyde $^{18}$F-FBA, the acylation approach revealed lower RCYs and RCP, most probably due to the hydrolysis of the labeled synthon and slower overall reaction kinetics. When compared to the high labeling efficiencies for $^{18}$F-DCFPyl and EuE-k-$\beta$-a-$^{18}$F-FPyl, the conjugation efficiency of $^{18}$F-PSMA-1007 was found to be significantly decreased, resulting in markedly lower overall RCYs. Cardinale et al. explained the low conversion rate with the formation of an inner salt of the terminal glutamic acid and the amino group that might reduce the nucleophilicity of the amino group [1]. In contrast, the synthesis of EuE-k-$^{18}$F-FBOA via oxime ligation with $^{18}$F-FBA resulted in good RCYs with less amount of precursor peptide needed. Moreover, nearly no side-product formation was observed. Therefore, we assume that the final HPLC purification might be replaceable by a SPE extraction in an automated production of EuE-k-$^{18}$F-FBOA. Furthermore, due to ease of labeling, this approach should be well suited for automated radiosynthesis in clinical routine.

Regarding the ligand design, we focused on the improvement of the structural requirements for favorable in vivo and in vitro PSMA-targeting characteristics. As expected, all tracers show high affinity towards PSMA, although the affinity of F-DCFPyl was found to be significantly lower, and more comparable to those of $^{68}$Ga-HBED-CC and $^{68}$Ga-PSMA-I&T [24, 25].

Apart from a low nanomolar receptor affinity, the extent of peptide internalization is another, potentially even more important factor for efficient targeted tracer uptake. A study by Liu et al. has indicated that the internalization efficiency of a PSMA-inhibitor complex depends on the extent of PSMA conformational changes, resulting from different inhibition modes for PSMA ligands [26]. The binding of a ligand can either support or inhibit the interaction between the cytoplasmic tail of PSMA with clathrin and the clathrin adaptor protein-2 complex and thus alter the internalization efficiency [26, 27]. However, reports about structural features of PSMA inhibitors, which influence the internalization potency and to what extent, are scarce. A moderate correlation between increasing lipophilicity and higher cellular uptake of an inhibitor has been reported recently [28, 29]. However, in this study, the most hydrophilic compound EuE-k-$\beta$-a-$^{18}$F-FPyl revealed markedly enhanced internalization compared to all compounds investigated.

Additionally, based on our unreported findings and on recently published data, there seems to be no direct correlation between PSMA affinity and internalization efficiency of an inhibitor [28, 29]. This assumption is consistent with our findings in which $^{18}$F-DCFPyl and $^{18}$F-PSMA-1007 showed identical internalization efficiency, despite their IC$_{50}$ values being approximately twofold apart. Yet in contrast, the enhanced affinity of the EuE-based inhibitors was associated with 1.4-fold and 2.7-fold higher internalization rates in PSMA-expressing cells in comparison to the reference ligands. Therefore, further studies are needed to address these questions thoroughly.

In addition, the hydrophilicity (logP) and the extent of plasma protein binding significantly contributes to the performance and dominates the in vivo pharmacokinetics of a...
given radiopharmaceutical. An ideal PSMA-targeted PET tracer show a delayed urinary excretion with a slight shift towards hepatobiliary clearance, which is especially important for the detection of primary PCa and the early pattern of lymph node metastasis. Whereas EuE-k-18F-FBOA and \( ^{18}\text{F}-\text{DCFPyl} \) fulfill these criteria (logP \(-2.6\rightarrow -3\)), EuE-k-β-a-18F-FPyl exhibits a lower lipophilicity \((-4.2\)\) and \( ^{18}\text{F}-\text{PSMA-1007} \) a higher lipophilicity \((-1.6\)\), resulting in 98% plasma protein binding and thus the slowest excretion kinetics for \( ^{18}\text{F}-\text{PSMA-1007} \) as demonstrated in microPET imaging and biodistribution studies (Figs. 3 and 4; Additional file 1: Figure S5). In addition, metabolic studies of \( ^{18}\text{F}-\text{PSMA-1007} \) showed irreducible degradation in the urine (2%) and kidneys (4%), probably based on the intrinsic susceptibility of L-amino acid peptides towards degradation by endopeptidases (Additional file 1: Figure S4) [17].

As hypothesized, both EuE-based ligands showed straightforward clearance kinetics in micro PET images and biodistribution studies in LNCaP-xenograft-bearing mice. In addition to the fast renal clearance of these inhibitors, especially for EuE-k-18F-FBOA, almost no background activity or tracer accumulation in non-target tissue was observed (Figs. 3 and 4). Due to its high hydrophilicity and therefore predominant renal excretion, exclusively, EuE-k-β-a-18F-FPyl displayed no uptake in the liver. As anticipated, along with high plasma protein binding and long blood circulation,
18F-PSMA-1007 displayed a delayed blood clearance (Additional file 1: Figure S5) and non-specific accumulation in non-target tissue, like the heart, lungs, pancreas, stomach, intestine, muscle, and bone, which increases within 2 h p.i. (Fig. 4). Thus, later imaging time points may be required for high-contrast PCa imaging using 18F-PSMA-1007, which is in accordance with observations made in initial patient studies [10].

In terms of similarity, all ligands showed high but variable accumulation in murine PSMA-expressing organs, like the kidneys, the adrenal glands, and the spleen [22, 23]. The observed variability of respective tracer accumulation in these organs does not directly correlate with the determined PSMA affinity and accumulation in human LNCaP xenografts of the compounds investigated. These observations may be explained by considerable differences in affinities of the respective inhibitors for PSMA expressed on human (xenograft) tumors and murine PSMA expressed on mouse tissues.

Particularly, the uptake of 18F-PSMA-1007 in the spleen was significantly increased compared to the other inhibitors (Fig. 4). This variable uptake of PSMA-targeted radioligands in mouse spleen was already observed by us and others [13, 30–32]. Although PSMA (GCPII)-expression in mouse spleen is documented on the mRNA-level [23], it is not detectable on the protein level [22]. Nevertheless, blockable tracer uptake in mouse spleen has been observed for a multitude of small urea-based PSMA inhibitors, albeit at very variable levels (from 0.6% IA/g [13] to 47% IA/g [31] at 1 h p.i.), which does not correlate with the relative PSMA affinities of the compounds investigated. Our own data have already hinted towards a strong dependence of splenic tracer uptake on the respective mouse strain used [31], whereas tracer uptake in human LNCaP xenografts accurately reflects the respective expression density of human PSMA and thus allows valid comparisons [13, 25, 30, 32]. Therefore, blockable uptake of a given radiolabeled PSMA inhibitor in the mouse spleen, as well as other murine PSMA-expressing organs is a qualitative indicator for successful PSMA-targeting, but cannot provide quantitative and relative information on its PSMA-targeting performance in humans.

Interestingly, EuE-k-18F-FBOA and 18F-DCFPyl revealed significantly lower accumulation in the kidneys with faster renal clearance compared to EuE-k-β-a-18F-FPyl and 18F-PSMA-1007, which showed even higher accumulation after 2 h p.i. (Fig. 4). For 18F-PSMA-1007, this effect may be linked to the delayed delivery of the tracer caused by the higher activity levels in the blood pool (Additional file 1: Figure S5). For EuE-k-β-a-18F-FPyl, redistribution effects may contribute to this effect.

Since tracer internalization is a key factor for the efficiency of tumor uptake and retention, the higher internalization of EuE-k-18F-FBOA and EuE-k-β-a-18F-FPyl and the enhanced PSMA-targeting characteristics compared to 18F-DCFPyl and 18F-PSMA-1007 correlates with the approximately 50% enhanced tumor accumulation in micro PET imaging and biodistribution studies (12.7 ± 2.0% IA/g, 13.0 ± 1.0% IA/g, 1 h p.i. vs 7.3 ± 1.0% IA/g (18F-DCFPyl), 7.1 ± 1.5% IA/g (18F-PSMA-1007), 1 h p.i.) in LNCaP-tumor-xenografts (Figs. 3 and 4). Additionally, EuE-k-β-a-18F-FPyl revealed higher tumor retention 2 h p.i. The better tumor-to-liver ratios for EuE-k-β-a-18F-FPyl were occasioned by the enhanced hydrophilicity, whereas EuE-k-18F-FBOA revealed better tumor-to-kidney ratios compared to the reference ligands, explainable by the low accumulation and fast renal clearance leading to high-contrast PET imaging (Figs. 3 and 5).

Based on the promising preclinical results obtained for EuE-k-18F-FBOA (1) a 79-year-old mCRPC patient (PSA 392 ng/ml) was imaged under compassionate use. The agent was applied in compliance with The German Medicinal Products Act, Arzneimittelgesetz (AMG) §13 2b, and in accordance with the responsible regulatory body (Government of Oberbayern). The patient underwent PET/MR imaging 62 min after injection of 158 MBq of EuE-k-18F-FBOA (Fig. 6).

Images show the typical biodistribution of PSMA ligands with minimal blood pool retention. Based on the high hydrophilicity and low plasma protein binding of EuE-k-18F-FBOA, the rapid renal washout and fast blood clearance allowed high-contrast PCa PET imaging at 1 h p.i. EuE-k-18F-FBOA revealed high uptake in the kidneys (SUVmean 14.0), the salivary glands (SUVmean 5.8), and the spleen (SUVmean 6.1) and moderate uptake in the liver (SUVmean 6.4), respectively. Figure 6 demonstrates intensive PSMA-ligand uptake in multiple bone and
lymph node metastases with mean SUV_{mean} 14.7 (range 9.2–19) and mean SUV_{max} 21.6 (range 15.4–28.2). Notably, even tiny subcentimeter lymph node metastases (dotted arrows) showed intense uptake of (1) and were easily detectable. These results indicate high potential of EuE-k-^{18}F-FBOA (1) for the detection of metastatic PCa even at early imaging time points.

**Conclusion**
The $^{18}$F-labeled EuE-based PSMA ligands EuE-k-^{18}F-FBOA and EuE-k-β-a-^{18}F-FPyl showed excellent PSMA-affinities, pronounced hydrophilicity, low plasma protein binding, low unspecific uptake, and significantly higher tumor accumulation in mice than those obtained with the two recently introduced PSMA PET tracers, $^{18}$F-PSMA-1007 and $^{18}$F-DCFPy. In addition, the preclinical comparison of the four $^{18}$F-labeled radiopharmaceuticals revealed significant different in vivo behaviors that might have an impact of the relative performance of these tracers in human studies. Based on high and persistent accumulation in targeted tissue, faster renal clearance of EuE-k-^{18}F-FBOA resulted in better high-contrast micro-PET imaging and higher tumor-to-organ ratios at early time points of 1 h p.i. compared to EuE-k-β-a-^{18}F-FPyl. Therefore, we expect EuE-k-^{18}F-FBOA to be more promising for further clinical investigations, additionally, due to its reliable radiolabeling procedure facilitating the suitable transfer for automatization in clinical routine.

**Additional file**

Additional file 1: Supporting information contains the description of the chemical synthesis and radiolabeling of all compounds investigated.

**Abbreviations**

% IA/g: Percentage of injected activity per gram; % IA/mL: Percentage of injected activity per unit volume; $^{18}$F-FBA: $^{18}$F-fluorobenzaldehyde; $^{18}$F-FPyl-TFP: 2,3,5,6-Tetrafluorophenylester-6-$^{18}$F-fluoronicotinate; AMG: Arzneimittelgesetz; DMEM: Dulbecco’s modified Eagle’s medium; EuE: Glu-urea-Glu; FCS: Fetal calf sera; HSA: Human serum albumin; IC_{50}: Half maximal inhibitory concentration; KuE: Lys-urea-Glu; LNCaP: Lymph node carcinoma of the prostate; PCa: Prostate cancer; PET: Positron emission tomography; PMPA: 2-Phosphonomethyl pentanedioic acid; PSMA: Prostate-specific membrane antigen; RP-HPLC: Reversed phase high-performance liquid chromatography; SCID: Severe combined immunodeficiency; SD: Standard deviation; SUV: Standardized uptake value; TFA: Trifluoroacetic acid

**Acknowledgements**

We thank Sybille Reder and Markus Mittelhäuser for the small-animal PET imaging and Michael Herz for supplying $^{18}$F-fluoride for the radiolabelling.

**Funding**

M.Schw has received funding from the European Union Seventh Framework Program (FP7) under Grant Agreement No. 294582 ERC Grant MUMI. The development of $^{18}$F-PSMA inhibitors was supported by SFB 824 (DFG Sonderforschungsbereich 824, Project Z1) from the Deutsche Forschungsgemeinschaft, Bonn, Germany. M.E. received funding from the SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft, Bonn, Germany.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article and its supplementary information file.

**Authors’ contributions**

SR carried out the design, synthesis, $^{18}$F-labeling of the tracers; performed the preclinical in vivo and in vitro evaluation; and drafted the manuscript. ASch was involved in the in vitro and in vivo evaluation, performed the data evaluation and interpretation, and revised the manuscript. ME carried out the proof-of-principle PET/CT and PET/MR imaging of the patients as well as image and data interpretation, drafted the human studies, and revised the final manuscript. MScho supported the preclinical evaluation of $^{18}$F-labeled PSMA inhibitors and participated in the data interpretation and in revising
the manuscript. TG synthesized the 18F-labeling precursor and revised the final manuscript. BHJ was involved in the 18F-labeling of the tracers and revised the final manuscript. MSchw supported the preclinical and clinical evaluation of 18F-labeled PSMA inhibitors and participated in the data interpretation and in revising the final manuscript. HJW initiated the development and evaluation of the EuE-based inhibitors, participated in the data interpretation and in writing the manuscript and revising the final manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All animal experiments were conducted in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval no. 55.2-1-54-2532-71-13). A patient was imaged under compassionate use. The agent was applied in compliance with The German Medicinal Products Act, AMG §13 2b and in accordance with the responsible regulatory body (Government of Oberbayern). The patient signed a written informed consent form for the purpose of anonymized evaluation and publication of the data.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Chair of Pharmaceutical Radiochemistry, Technical University Munich, Walther-Meissner-Strasse 3, 85748 Garching, Germany. 2Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Ismaningerstr. 22, 81675 Munich, Germany.

Received: 26 January 2018 Accepted: 23 March 2018
Published online: 12 April 2018

References
1. Cardinale J, et al. Preclinical evaluation of [(18)F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2016;57(12):181768.
2. Chen Y, et al. 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl-ureido}-pen tane) acid, [(18)F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17(24):7645–53.
3. Malik N, et al. Radiosynthesis of a new PSMA targeting ligand [(18)F]FPy-DUPA-Pep. Appl Radiat Isot. 2011;69(7):1014–8.
4. Cho SY, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCBFC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53(12):1883–91.
5. Malik N, et al. Radiolabeling of PSMA-HBED via Alk18F(2+) chelation and biological evaluations in vitro. Mol Imaging Biol. 2015;17(6):777–85.
6. Lapi SE, et al. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med. 2009;50(12):2042–8.
7. Rowe SP, et al. PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18(3):411–9.
8. Mease RC, et al. N,N-[N(S)-1,3-Dicarboxypropyl]carbamoyl]I-
-[(18)fluoro benzyl]-L-cysteine, [(18)F]DCBFC, a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14(10):3036–43.
9. Szabo Z, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565–74.
10. Afshar-Oromieh A, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705.
11. Giesel FL, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.
12. Eiber M, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58(Supplement 2):675–765.
13. Kubratne SA, et al. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99mTc)-radioimaging agents. Mol Pharm. 2009;6(3):790–800.
14. Hiller SM, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54(8):1369–76.
15. Giesel FL, et al. 18F labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the therapeutic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1029–30.
16. Vallo K, et al. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci. 2003;92(11):2236–48.
17. Weineisen M, et al. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):014–0063.
18. B Neumaier, B Zlatopolskiy, R Richarz, P Kräpf, Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a Psm-specific pet-tracer. 2016, Max-planck-gesellschaft zur förderung der wissenschaften e.V.
19. Richarz R, et al. Neither azeotropic drying, nor base nor other additives: a minimalist approach to 18F-labeling. Org Biomol Chem. 2014;12(40):8094–9.
20. Chen Y, et al. Radiolabeled prostate-specific membrane antigen (PSMA)-based imaging agents for prostate cancer. J Med Chem. 2008;51(24):7933–43.
21. Bouvet V, et al. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. EJNMMI Res. 2016;6:40.
22. Baccic DJ, et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome. 2001;12(2):117–23.
23. Ihoushova K, et al. GCPII variants, paralogs and orthologs. Curr Med Chem. 2012;19(9):1316–22.
24. Eder M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals. 2014;7(7):779–96.
25. Weineisen M, et al. 68Ga- and 177Lu-labeled PSMA &T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–76.
26. Liu T, et al. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramide peptidomimetics. Biochemistry. 2008;47(48):12658–60.
27. Rajasekaran SA, et al. A novel cytoplasmic tail MXXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4833–45.
28. Benesova M, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTAGA-conjugated PSMA inhibitors. J Med Chem. 2016;59(5):1761–75.
29. Wustemann T, et al. Design of internalizing PSMA-specific Glu-ureido-based radiotherapeutics. Theranostics. 2016;6(8):1085–95.
30. Benesova M, et al. PSMA-617-a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer. J Nuc Med. 2015;56(3).
31. Schottellius M, et al. 111InPSMA-I&T: expanding the spectrum of PSMA-I&T studies. J Nucl Med. 2015;56(8):1169–76.
32. Eder M, et al. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate. 2014;74(6):659–68.